|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
TransTech Pharma, Inc. Release: Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients
10/29/2012 2:38:56 PM
HIGH POINT, N.C.--(BUSINESS WIRE)--A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to show clinical benefit from research on the receptor for advanced glycation endproducts (RAGE), a new biochemical target in Alzheimer’s disease treatment. TransTech Pharma, Inc. of High Point, North Carolina discovered, developed and owns all rights to this drug candidate.
|
|
|
|
|
|
|
|
|
|
|